Ozempic face: A new challenge for facial plastic surgeons

Tay, Jing Qin

doi:10.1016/j.bjps.2023.04.057

Cited by 2 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dermal fillers, fat autografting, and collagen stimulators can be used to re-volumize and resurface the temple, tear trough, midface, nasolabial fold, and jowl. 47 Radiofrequency, microneedling, and laser skin tightening modalities can revitalize the skin and promote collagen and elastin production. Face and neck lifting can efface wrinkles and remove skin excess, with an understanding that superficial musculoaponeurotic system elevation may be necessary to optimize results in this population.…”

Section: Glp-1 Receptor Agonist Therapy In Plastic Surgerymentioning

confidence: 99%

Injectable Weight Loss Medications in Plastic Surgery: What We Know, Perioperative Considerations, and Recommendations for the Future

O’Neill,

Wiegmann,

Parrella

et al. 2024

Plastic and Reconstructive Surgery - Global Open

View full text Add to dashboard Cite

Summary: Obesity is a major epidemic plaguing American society. Injectable subcutaneous medications initially designed for use in type 2 diabetes management, such as semaglutide and other glucagon-like peptide-1 receptor agonists, are rapidly gaining popularity for their effects on weight. These drugs (Ozempic, Wegovy, Saxenda, and Mounjaro) are ubiquitous on social media and are promoted by celebrities across all demographics. “Ozempic face” and “Ozempic butt” are now mainstream concepts highlighting the morphologic changes that occur with these medications. There is a paucity of literature available on the impact of these medications for plastic surgeons and their patients. As use becomes widespread, it is important for plastic surgeons to understand their indications, contraindications, appropriate perioperative management, and impact on plastic surgery procedures.

show abstract

Section: Glp-1 Receptor Agonist Therapy In Plastic Surgerymentioning

confidence: 99%

Injectable Weight Loss Medications in Plastic Surgery: What We Know, Perioperative Considerations, and Recommendations for the Future

O’Neill,

Wiegmann,

Parrella

et al. 2024

Plastic and Reconstructive Surgery - Global Open

View full text Add to dashboard Cite

show abstract

Current Weight Loss Medications: What Plastic Surgeons Should Know

Wirth,

Shaffrey,

Bay

et al. 2023

Aesthetic Surgery Journal

View full text Add to dashboard Cite

The World Health Organization (WHO) estimates that over 650 million adults are obese worldwide. Recently, anti-diabetic medications have rapidly become popular as weight loss medications. With the rising prevalence of obesity and the increasing demand for aesthetic procedures, it is anticipated that a growing number of patients presenting for consultation will be prescribed these medications. Therefore, it is critical for practicing plastic surgeons to understand their potential synergistic effects and safety considerations. This manuscript explores the potential benefits and considerations of anti-diabetic medications in plastic surgery patients for weight loss therapy. The authors discuss the mechanisms of action, clinical efficacy, potential side effects, and relevant considerations for incorporating these medications into plastic surgery practices and medical spas.

show abstract

Ozempic face: A new challenge for facial plastic surgeons

Cited by 2 publications

References 3 publications

Injectable Weight Loss Medications in Plastic Surgery: What We Know, Perioperative Considerations, and Recommendations for the Future

Injectable Weight Loss Medications in Plastic Surgery: What We Know, Perioperative Considerations, and Recommendations for the Future

Current Weight Loss Medications: What Plastic Surgeons Should Know

Contact Info

Product

Resources

About